NeoGenomics, Inc. (NASDAQ:NEO) Stake Boosted by First Light Asset Management LLC

First Light Asset Management LLC grew its position in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 3.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,167,585 shares of the medical research company's stock after purchasing an additional 91,030 shares during the period. NeoGenomics makes up 5.0% of First Light Asset Management LLC's holdings, making the stock its 7th largest position. First Light Asset Management LLC owned approximately 2.47% of NeoGenomics worth $52,202,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SBI Securities Co. Ltd. purchased a new position in NeoGenomics during the 4th quarter worth approximately $26,000. Versant Capital Management Inc raised its holdings in shares of NeoGenomics by 174.9% during the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company's stock worth $30,000 after purchasing an additional 1,142 shares during the last quarter. Sterling Capital Management LLC boosted its holdings in NeoGenomics by 788.7% in the fourth quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company's stock valued at $61,000 after purchasing an additional 3,289 shares during the last quarter. Smartleaf Asset Management LLC grew its position in NeoGenomics by 203.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company's stock worth $70,000 after purchasing an additional 2,787 shares during the period. Finally, Blue Trust Inc. raised its stake in shares of NeoGenomics by 33.2% during the 4th quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company's stock valued at $73,000 after buying an additional 1,103 shares during the last quarter. Institutional investors and hedge funds own 98.50% of the company's stock.

NeoGenomics Price Performance

Shares of NASDAQ NEO traded up $0.44 during trading on Friday, hitting $7.70. The company had a trading volume of 3,644,552 shares, compared to its average volume of 1,075,572. The firm has a market capitalization of $990.66 million, a price-to-earnings ratio of -12.42 and a beta of 1.41. The stock has a fifty day simple moving average of $9.40 and a two-hundred day simple moving average of $13.27. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. NeoGenomics, Inc. has a fifty-two week low of $6.08 and a fifty-two week high of $19.12.

NeoGenomics (NASDAQ:NEO - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.06). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The firm had revenue of $168.04 million during the quarter, compared to analyst estimates of $171.38 million. During the same quarter in the previous year, the firm posted ($0.02) earnings per share. The company's quarterly revenue was up 7.6% on a year-over-year basis. On average, research analysts expect that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on NEO. Benchmark lowered NeoGenomics from a "buy" rating to a "hold" rating in a report on Monday, January 13th. Bank of America cut their target price on shares of NeoGenomics from $19.00 to $16.00 and set a "neutral" rating for the company in a report on Wednesday, February 19th. The Goldman Sachs Group lowered their price target on shares of NeoGenomics from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday. Morgan Stanley dropped their price target on shares of NeoGenomics from $17.00 to $10.00 and set an "equal weight" rating on the stock in a research report on Thursday. Finally, Needham & Company LLC decreased their price objective on shares of NeoGenomics from $18.00 to $8.50 and set a "buy" rating for the company in a research report on Tuesday. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $14.50.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.